The Online Investor
Daily M&A
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Mergers & Acquisitions

By The Online Investor Staff, updated Mon., Dec. 9, 9:10 AM

Slide #49. Novartis The Medicines Company

Acquirer: Novartis (NVS)
Acquiree: The Medicines Company (MDCO)
Details: Novartis announced today that it has entered into an agreement and plan of merger with The Medicines Company (NASDAQ:MDCO) to acquire the US-based biopharmaceutical company for USD 85.00 per share in cash, valuing the company at approximately USD 9.7 billion on a fully diluted equity basis. The offer price represents a premium of approximately 41% over The Medicines Company's 30-day (to November 22, 2019) volume weighted average price of USD 60.33 and approximately 24% premium over The Medicines Company's closing share price of USD 68.55 on November 22, 2019 which represented a fully diluted equity value of approximately USD 7.7 billion when including the impact of outstanding stock options and convertible debt. The transaction has been unanimously approved by the Boards of Directors of both companies.

Novartis is a multinational group focusing on the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals and also including generic pharmaceuticals and eye care products. Co. comprises three global operating divisions: Innovative Medicines Division, which researches, develops, manufactures, distributes and sells patented prescription medicines; Sandoz Division, which develops, manufactures, distributes and sells prescription medicines as well as pharmaceutical active substances; and Alcon Division, which researches, develops, manufactures, distributes and sells eye care products.

Open the NVS Page at The Online Investor »

Novartis is a multinational group focusing on the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals and also including generic pharmaceuticals and eye care products. Co. comprises three global operating divisions: Innovative Medicines Division, which researches, develops, manufactures, distributes and sells patented prescription medicines; Sandoz Division, which develops, manufactures, distributes and sells prescription medicines as well as pharmaceutical active substances; and Alcon Division, which researches, develops, manufactures, distributes and sells eye care products.

Open the MDCO Page at The Online Investor »

Company Name:  Novartis AG Basel
Website:  www.novartis.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding NVS:  7
Total Market Value Held by ETFs:  $66.95M
Total Market Capitalization:  $257.91B
% of Market Cap. Held by ETFs:  0.03%
Company Name:  Medicines Co (The)
Website:  www.themedicinescompany.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding MDCO:  47
Total Market Value Held by ETFs:  $1.37B
Total Market Capitalization:  $6.70B
% of Market Cap. Held by ETFs:  20.46%
 

December 9, 2019    9:10 AM Eastern
Quotes delayed 20 minutes


Mergers & Acquisitions | www.TheOnlineInvestor.com | Copyright © 1998 - 2019, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.